Pasithea Therapeutics Corp. (KTTA)
Automate Your Wheel Strategy on KTTA
With Tiblio's Option Bot, you can configure your own wheel strategy including KTTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KTTA
- Rev/Share 0.0872
- Book/Share 1639.8015
- PB 0.0007
- Debt/Equity 0.0
- CurrentRatio 4.0151
- ROIC -0.2547
- MktCap 8857857.0
- FreeCF/Share -1318.7951
- PFCF -0.0009
- PE -0.0029
- Debt/Assets 0.0
- DivYield 0
- ROE -0.9953
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the pricing of a public offering of 80,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.75 per share of …
Read More
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability -- -- Tablet steady state showing Cmax/Cmin ratio
Read More
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
Read More
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Pasithea Therapeutics (Nasdaq: KTTA) prices $5M public offering to fund clinical trials, R&D, and corporate initiatives; closing expected May 7, 2025.
Read More
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.
Read More
About Pasithea Therapeutics Corp. (KTTA)
- IPO Date 2021-09-15
- Website https://www.pasithea.com
- Industry Biotechnology
- CEO Tiago Reis Marques
- Employees 4